You are here: Industry Insights > DUR-928

News List

First Patient Dosed in DUR-928 Study for Severe Alcohol-Associated Hepatitis americanpharmaceuticalreview
January 29, 2021
DURECT has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.
First Patient Dosed in DUR-928 Study in COVID-19 Patients with Acute Liver, Kidney Injury americanpharmaceuticalreview
September 30, 2020
DURECT has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury.
DURECT Announces Positive Topline Data from NASH Study americanpharmaceuticalreview
June 02, 2020
DURECT Corporation announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients.
DURECT Announces Top-Line Results from Psoriasis Clinical Trial americanpharmaceuticalreview
January 03, 2020
DURECT announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study ...